Aberdeen Group plc Sells 110,587 Shares of Sionna Therapeutics, Inc. $SION

Key Points

• Aberdeen Group plc reduced its stake in Sionna by 11.6% in Q4, selling 110,587 shares and leaving it with 839,960 shares (~1.88%) valued at about $34.56 million.
• Insiders and major holders sold stock: Director Peter A. Thompson sold 29,063 shares at $44.58 and TPG sold 250,000 shares at $40, with insiders offloading 311,906 shares (~$12.76M) in the last three months while still owning 3.90% of the company.
• Analyst sentiment is a "Moderate Buy" consensus with a $50.57 average target, and Sionna recently beat quarterly EPS estimates (reported -$0.46 vs. consensus -$0.61); market cap is roughly $1.82 billion.

Aberdeen Group plc lessened its stake in shares of Sionna Therapeutics, Inc. (NASDAQ:SION - Free Report) by 11.6% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 839,960 shares of the company's stock after selling 110,587 shares during the period. Aberdeen Group plc owned about 1.88% of Sionna Therapeutics worth $34,556,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. Braidwell LP purchased a new stake in Sionna Therapeutics during the second quarter worth $18,770,000. Vanguard Group Inc. raised its position in shares of Sionna Therapeutics by 81.4% in the 3rd quarter. Vanguard Group Inc. now owns 1,143,154 shares of the company's stock worth $33,620,000 after acquiring an additional 512,803 shares in the last quarter. Viking Global Investors LP lifted its stake in shares of Sionna Therapeutics by 8.2% during the 2nd quarter. Viking Global Investors LP now owns 3,195,181 shares of the company's stock worth $55,436,000 after purchasing an additional 242,427 shares during the last quarter. Millennium Management LLC lifted its stake in shares of Sionna Therapeutics by 1,425.5% during the 3rd quarter. Millennium Management LLC now owns 214,085 shares of the company's stock worth $6,296,000 after purchasing an additional 200,051 shares during the last quarter. Finally, Geode Capital Management LLC lifted its stake in shares of Sionna Therapeutics by 113.4% during the 2nd quarter. Geode Capital Management LLC now owns 289,275 shares of the company's stock worth $5,020,000 after purchasing an additional 153,712 shares during the last quarter.

Analysts Set New Price Targets

A number of brokerages have commented on SION. BTIG Research reiterated a "buy" rating and issued a $58.00 target price on shares of Sionna Therapeutics in a report on Monday, March 2nd. Raymond James Financial restated a "strong-buy" rating and issued a $53.00 price target on shares of Sionna Therapeutics in a report on Monday, January 5th. Wall Street Zen raised shares of Sionna Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, December 13th. UBS Group reiterated a "buy" rating on shares of Sionna Therapeutics in a research note on Monday, March 2nd. Finally, Lifesci Capital upgraded shares of Sionna Therapeutics to a "strong-buy" rating in a research note on Wednesday, February 25th. Two investment analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and two have given a Sell rating to the company. According to data from MarketBeat.com, Sionna Therapeutics currently has an average rating of "Moderate Buy" and a consensus target price of $50.57.

Insiders Place Their Bets

In related news, Director Peter A. Thompson sold 29,063 shares of the firm's stock in a transaction dated Tuesday, February 3rd. The stock was sold at an average price of $44.58, for a total transaction of $1,295,628.54. Following the sale, the director directly owned 3,530,702 shares of the company's stock, valued at $157,398,695.16. This trade represents a 0.82% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Tpg Gp A, Llc sold 250,000 shares of Sionna Therapeutics stock in a transaction that occurred on Thursday, January 22nd. The shares were sold at an average price of $40.00, for a total value of $10,000,000.00. Following the transaction, the insider owned 6,494,962 shares of the company's stock, valued at approximately $259,798,480. This represents a 3.71% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 311,906 shares of company stock valued at $12,759,732. Company insiders own 3.90% of the company's stock.

Sionna Therapeutics Stock Performance

Shares of NASDAQ:SION opened at $40.49 on Friday. Sionna Therapeutics, Inc. has a twelve month low of $7.26 and a twelve month high of $45.00. The company has a market cap of $1.82 billion, a PE ratio of -20.76 and a beta of 3.01. The company's 50 day moving average is $37.88 and its 200 day moving average is $37.38.

Sionna Therapeutics (NASDAQ:SION - Get Free Report) last announced its quarterly earnings data on Monday, March 2nd. The company reported ($0.46) EPS for the quarter, beating the consensus estimate of ($0.61) by $0.15.

About Sionna Therapeutics

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.